Please wait while the formulary information is being retrieved.
Drug overview for BRONCHITOL (mannitol):
Generic name: MANNITOL (MAN-i-tol)
Drug class: Cystic Fibrosis - Osmotic Agents Inhaled
Therapeutic class: Respiratory Therapy Agents
Mannitol is an osmotic diuretic.
No enhanced Uses information available for this drug.
Generic name: MANNITOL (MAN-i-tol)
Drug class: Cystic Fibrosis - Osmotic Agents Inhaled
Therapeutic class: Respiratory Therapy Agents
Mannitol is an osmotic diuretic.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for BRONCHITOL (mannitol) have been approved by the FDA:
Indications:
Respiratory cystic fibrosis
Professional Synonyms:
Respiratory complications of cystic fibrosis
Indications:
Respiratory cystic fibrosis
Professional Synonyms:
Respiratory complications of cystic fibrosis
The following dosing information is available for BRONCHITOL (mannitol):
The dosage, concentration of solution, and rate of administration of mannitol vary with the condition being treated and the patient's fluid requirements, urinary output, and response to the drug.
Patients with marked oliguria or suspected inadequate renal function should receive a dose of about 0.2 g/kg or 12.5 g as a 15 or 20% solution infused over a period of 3-5 minutes to test renal response before mannitol therapy is initiated.
A response is considered adequate if at least 30-50 mL of urine per hour is excreted over the next 2-3 hours. If an adequate response is not attained, a second test dose may be given. If a satisfactory response is not obtained after the second test dose, the patient should be reevaluated and mannitol should not be used.
Mannitol dosage requirements for patients 12 years of age and younger have not been established. However, some clinicians have suggested the following dosages for pediatric patients. In oliguria or anuria, a test dose of 0.2
g/kg or 6 g/m2 may be given as a single dose over 3-5 minutes. For therapeutic purposes, 2 g/kg or 60 g/m2 may be given. For the treatment of edema and ascites, this dose may be given as a 15 or 20% solution over 2-6 hours.
To reduce cerebral or ocular edema, the dose may be given as a 15 or 20% solution over 30-60 minutes. For the treatment of intoxications, the drug may be given as a 5 or 10% solution as needed.
Patients with marked oliguria or suspected inadequate renal function should receive a dose of about 0.2 g/kg or 12.5 g as a 15 or 20% solution infused over a period of 3-5 minutes to test renal response before mannitol therapy is initiated.
A response is considered adequate if at least 30-50 mL of urine per hour is excreted over the next 2-3 hours. If an adequate response is not attained, a second test dose may be given. If a satisfactory response is not obtained after the second test dose, the patient should be reevaluated and mannitol should not be used.
Mannitol dosage requirements for patients 12 years of age and younger have not been established. However, some clinicians have suggested the following dosages for pediatric patients. In oliguria or anuria, a test dose of 0.2
g/kg or 6 g/m2 may be given as a single dose over 3-5 minutes. For therapeutic purposes, 2 g/kg or 60 g/m2 may be given. For the treatment of edema and ascites, this dose may be given as a 15 or 20% solution over 2-6 hours.
To reduce cerebral or ocular edema, the dose may be given as a 15 or 20% solution over 30-60 minutes. For the treatment of intoxications, the drug may be given as a 5 or 10% solution as needed.
Mannitol injections are administered by IV infusion. An administration set with a filter should be used for infusion of injections containing 20% or more, since mannitol crystals may be present. For transurethral prostatic resection, mannitol irrigation solutions are instilled into the bladder via an indwelling urethral catheter.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| BRONCHITOL 40 MG INHALE CAP | Maintenance | Adults inhale the contents of 10 capsules (400 mg) by inhalation route 2 times per day |
No generic dosing information available.
The following drug interaction information is available for BRONCHITOL (mannitol):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for BRONCHITOL (mannitol):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 8 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| 30 day risk period post-myocardial infarction |
| Acute asthma attack |
| Aortic aneurysm with dissection |
| Arterial aneurysm |
| Brain aneurysm |
| Cerebrovascular accident |
| Exacerbation of chronic obstructive pulmonary disease |
| Severe uncontrolled hypertension |
There are 5 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Hemoptysis |
| Lower respiratory infection |
| Pneumothorax |
| Respiratory depression |
| Unstable angina pectoris |
There are 0 moderate contraindications.
The following adverse reaction information is available for BRONCHITOL (mannitol):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 3 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. |
Bronchospastic pulmonary disease Chest discomfort Dyspnea |
| Rare/Very Rare |
|---|
| None. |
There are 12 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Headache disorder |
Arthralgia Cough Dizziness Fever Hemoptysis Nausea Pain in oropharynx Rhinorrhea Sore throat Vomiting Wheezing |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for BRONCHITOL (mannitol):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Animal reproduction studies have not been performed with mannitol. It is also not known whether mannitol can caused fetal harm when administered to pregnant women. Mannitol should be used during pregnancy only when clearly needed.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for BRONCHITOL (mannitol):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for BRONCHITOL (mannitol)'s list of indications:
| Respiratory cystic fibrosis | |
| E84.0 | Cystic fibrosis with pulmonary manifestations |
Formulary Reference Tool